REGOMA-OSS: A LARGE, ITALIAN, MULTICENTER, PROSPECTIVE, OBSERVATIONAL, STUDY EVALUATING THE EFFICACY AND SAFETY OF REGORAFENIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA. (28-05-2024)

FRUQUINTINIB VERSUS PLACEBO IN PATIENTS WITH REFRACTORY METASTATIC COLORECTAL CANCER (FRESCO-2): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY. (21-05-2024)

ELACESTRANT  (ORAL SELECTIVE ESTROGEN RECEPTOR DEGRADER) VERSUS STANDARD ENDOCRINE THERAPY FOR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER: RESULTS FROM THE RANDOMIZED PHASE III EMERALD TRIAL. (14-05-2024)

RIPRETINIB IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOURS (INVICTUS): A DOUBLE, RANDOMISED, PLACEBO-CONTROLLED, PHASE 3 TRIAL. (07-05-2024)

EVENT-FREE SURVIVAL BY RESIDUAL CANCER BURDEN WITH PEMBROLIZUMAB IN EARLY-STAGE TRIPLE NEGATIVE BREAST CANCER (TNBC): EXPLORATORY ANALYSIS FROM KEYNOTE-522. (23-04-2024)

DOSTARLIMAB FOR PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER. (16-04-2024)

ENFORTUMAB VEDOTIN AND PERMBROLIZUMAB IN UNTREATED ADVANCED UROTHELIAL CANCER. (09-04-2024)

EXPANDED ACCESS PROGRAM (EAP) Marzo 2024: Farmaci disponibili in Italia nell’ambito di EXPANDED ACCESS PROGRAM (02-04-2024)

NANOLIPOSOMAL IRINOTECAN WITH FLUOROURACIL AND FOLINIC ACID IN METASTATIC PANCREATIC CANCER AFTER PREVIOUS GEMCITABINE-BASED THERAPY (NAPOLI-1): A GLOBAL, RANDOMISED, OPEN-LABEL, PHASE 3 TRIAL. (26-03-2024)

PD-L1 TESTING IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER: INTEROBSERVER AND INTERPLATFORM REPRODUCIBILITY OF CE-IVD ASSAYS FOR CPS AND IC SCORES. (19-03-2024)

EFFECT OF HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY ON CYTOREDUCTIVE SURGERY IN GASTRIC CANCER WITH SYNCHRONOUS PERITONEAL METASTASES: THE PHASE III GASTRIPEC-I TRIAL. (12-03-2024)

RANDOMIZED PHASE 3 STUDY COMPARING NEOADIUVANT CHEMOTHERAPY FOLLOWED BY SURGERY VERSUS CHEMORADIATION IN STAGE IB2-IIB CERVICAL CANCER: EORTC-5594. (05-03-2024)

HER2CLIMB-02: RANDOMIZED, DOUBLE-BLIND PHASE 3 TRIAL OF TUCATINIB AND TRASTUZUMAB EMTANSINE FOR PREVIOUSLY TREATED HER2-POSITIVE METASTATIC BREAST CANCER (26/02/2024)

ATEZOLIZUMAB CON O SENZA RADIOTERAPIA PER IL CARCINOMA SQUAMOSO AVANZATO DEL PENE (STUDIO PERICLES): TRIAL DI FASE II (19/02/2024)

STUDIO KATHERINE: T-DM1 adiuvante vs trastuzumab per EBC HER2+ con malattia residua dopo terapia neoadiuvante (chemioterapia e anti-HER2). Analisi finale della IDFS e seconda interim analisi della OS. (12/02/2024)

PROPHYLACTIC RADIATION THERAPHY VERSUS STANDARD OF CARE FOR PATIENTS WITH  HIGH-RISK ASYMPTOMATIC BONE METASTASIS: A MULTICENTER, RANDOMIZED PHASE II CLINICAL TRIAL. (05/02/2024)

PRACTICAL GUIDELINES FOR MOLECULAR TESTING OF CHOLANGIOCARCINOMA IN CLINICAL PRACTICE: ITALIAN EXPERTS’ POSITION PAPER. (29/01/2024)

CARDIOVASCULAR DISEASE IN TESTICULAR CANCER SURVIVORS: IDENTIFICATION OF RISK FACTORS AND IMPACT ON QUALITY OF LIFE (22/01/2023)

 

NUOVE INDICAZIONI RIMBORSATE DI TRASTUZUMAB DERUXTECAN: G.U. del 20 dicembre 2023

MONARCH 3: Risultati dell’analisi finale della sopravvivenza globale presentati al San Antonio Breast Cancer Symposium (SABCS) il 6 dicembre 2023 (09/01/2024)

STUDIO NATALEE. RIBOCICLIB ADIUVANTE NEL CARCINOMA MAMMARIO (19/12/2023)

STUDIO NATALEEE: ribociclib adiuvante nel carcinoma mammario (12/12/2023)

Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. (05/12/2023)

Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US (28/11/2023)

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer (21/11/2023)

Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US (14/11/2023)

Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US (novembre 2023)

Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial (ottobre 2023)

US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer (aprile 2023)

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial (aprile 2023)

Intra-individual comparison of ¹⁸F-sodium fluoride PET–CT and ⁹⁹mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial (febbraio 2023)

Blood Pressure Classification Using the 2017 ACC/AHA Guideline and Heart Failure in Patients with Cancer (febbraio 2023)

MARGITUXIMAB vs TRASTUZUMAB in pazienti con carcinoma mammario HER2-positivo avanzato pretrattato: risultati dello studio randomizzato di fase III SOPHIA (febbraio 2023)

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (gennaio 2023)

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial (gennaio 2023)